Navigation Links
UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure
Date:5/18/2012

CLEVELAND University Hospitals (UH) Case Medical Center and CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced promising results for the first-of-its-kind catheter-based Parachute Ventricular Partitioning Device, a Percutaneous Ventricular Restoration Therapy (PVRT) technology for patients with ischemic heart failure.

The two-year clinical results were presented today (May 18, 2012, 9 a.m.) during a Trials, Registries and Late Breaking Science Hot Line session at the 2012 EuroPCR Conference in Paris by UH Case Medical Center's Marco Costa, MD, Director of the Interventional Cardiovascular Center and the Research and Innovation Center at UH Case Medical Center's Harrington Heart & Vascular Institute and Professor, Case Western Reserve University School of Medicine.

Clinical data from the two first-in-human studies of the Parachute system presented today show meaningful and sustained low clinical events two years following treatment with the device.

"Heart failure is such a morbid condition, and in spite of our best efforts, we have so little to offer to our patients," said Dr. Costa, who was the national principal investigator for the initial trial. "Today we shared unprecedented news for cardiologists and heart failure patients. This novel technology could revolutionize care for our patients because the procedure is relatively simple and the outcomes are surprisingly remarkable for such a high-risk population."

Results from 31 treated U.S and European patients demonstrate a near-full New York Heart Association (NYHA) class improvement at two years compared to baseline (2.6 vs. 1.9, p-value<0.01). In addition, reduction in left ventricular volume was maintained out to two years (p-value<0.001). Furthermore, the procedure stabilized the remodeling process as demonstrated by no statistical change in post-procedure functional volume over a two-year period (
'/>"/>

Contact: Mike Ferrari
mike.ferrari@uhhospitals.org
216-844-7239
University Hospitals Case Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Ultrasensitive biosensor promising for medical diagnostics
2. Medical device, health professionals attend first national conference on value-driven engineering
3. Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship
4. Research!America says house funding levels for FY13 could undermine medical progress
5. Miniature pressure sensors for medical touch
6. Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings
7. Former Howard Hughes Medical Institute president to speak at Oliver Smithies Nobel Symposium
8. Nanotechnology in Medical Applications: The Global Market
9. T-rays technology could help develop Star Trek-style hand-held medical scanners
10. Open-source robotic surgery platform going to top medical research labs
11. Star Trek Tricorder revisited: Toward a genre of medical scanners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... University researchers is examining a new vaccine method that ... Wannemuehler and his team of researchers is hoping to ... use smaller doses and require only one trip to ... been prepared from killed bacteria. The vaccinated person,s immune ...
... available in French . A ... McGill Universitys Department of Microbiology and Immunology has discovered ... regulate the bodys autoimmune reactions may lose their effectiveness ... of type 1 diabetes. The study conducted on ...
... 2008 The Rwandan government, Great Ape Trust of ... Reserve is the future site of the Rwanda National ... ambitious forest restoration and ecological research efforts ever. The ... national conservation park comes less than three months after ...
Cached Biology News:Iowa State researchers look for smaller, cheaper, 1-dose vaccines 2Type 1 diabetes triggered by 'lazy' regulatory T-cells: McGill researchers 2Rwanda's Gishwati Forest selected as site for historic conservation project 2Rwanda's Gishwati Forest selected as site for historic conservation project 3
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
(Date:12/17/2014)... 17, 2014 Xeno Diagnostics has ... its most recent COLA inspection. Xeno has met ... national healthcare accreditation organization. Accreditation is earned only ... in day-to-day operations, demonstrate continued accuracy in the ... on-site laboratory survey. , While the ...
(Date:12/17/2014)... Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... disease, today announced the next step in its expanded ... solutions provider with the naming of current Chief Operating ... Executive Officer, while current Chairman of the Board and ... as Chairman. These changes are effective January 1, 2015. ...
(Date:12/17/2014)... Calif. , Dec. 17, 2014 ... a Phase 2 study evaluating the investigational oral ... of patients with severe, chronic itch who are ... of care, including topical steroids and antihistamines. ... change in Visual Analog Scale (VAS) itch score ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... DENVER, Colorado and JERUSALEM, September 16 Children,s,Hospital ... today,that Children,s Hospital is enrolling patients for the ExCell ... cord blood transplant sites,worldwide, five of which are children,s ... Hungary and Israel. The trial is researching the,safety and ...
... , ... Highly Automated QT(sm) and QT Beat-to-Beat(sm) to Improve Precision and Reduce Risk of False ... Rochester, ... core lab services and QT analysis, announced today that a top 15 pharmaceutical company ...
... , , , ST. LOUIS, ... be presenting at the UBS Global Life Sciences Conference on Monday, ... NY. Interested parties may listen via live audio broadcast over the ... the "Webcast" icon to access this file. , , ...
Cached Biology Technology:Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 2Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 3Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 4Top 15 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 2
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Black Polypropylene 384 Round Well Plate 70/Box...
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
Biology Products: